This clinical trial is focused on patients undergoing general abdominal, gynecologic, and urologic surgeries. The study is investigating the use of a medication called apixaban, which is an anticoagulant. Anticoagulants are medicines that help prevent blood clots. The trial aims to understand the benefits and risks of using apixaban to prevent blood clots, known as venous thromboembolism (VTE), in patients who are at a similar risk of developing these clots and experiencing bleeding during or after surgery.

Participants in the study will be randomly assigned to receive either apixaban or no anticoagulant treatment. Both groups will receive standard care, which includes mechanical methods to prevent blood clots, such as compression stockings. The study will monitor the occurrence of blood clots and any bleeding complications over a period of 90 days after surgery. The goal is to determine if apixaban provides a net benefit in preventing blood clots without causing significant bleeding.

The trial will also assess the safety of apixaban by tracking any major bleeding events, which could include a significant drop in hemoglobin levels, the need for blood transfusions, or bleeding that requires additional medical intervention. The study will help to clarify whether using apixaban is a safe and effective option for patients undergoing these types of surgeries.